1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Terumo Corporation

Terumo Corporation

TRUMF
Terumo CorporationUS flagOther OTC
13.60
USD
- -
- -
20.06BMarket Cap
Terumo Corporation
TRUMF
(Other OTC)

Recent

price

13.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
208.01
216.06
254.56
264.84
307.67
322.34
350.01
355.93
417.07
409.98
420.53
406.47
465.02
551.27
619.64
699.86
321.55
Revenue per Share
26.8
21.29
15.91
30.95
22.45
25.33
33.78
38.08
64.78
54.35
56.98
51.16
58.72
60.04
71.5
79.01
37.86
Basic EPS, GAAP
31.36
16.19
21.02
11.72
33.82
21.13
31.59
30.66
51.97
26.81
22.73
25.4
44.54
30.49
45.41
86.75
34.87
Free Cash Flow per Basic Share
4
4
4.37
5.5
6.37
7.25
8.8
10.05
11.24
13.37
13.71
14.01
15.51
18.75
21.52
24.06
11.02
Dividend per Share
233.96
251.25
191.26
216.71
232.78
252.41
279.71
382.33
445.36
468.43
497.82
538.87
585.61
613.63
667.72
712.49
699.7
Book Value per Share
188.92
203.23
53.81
93
126.06
159.05
147.35
13.78
75.22
156.77
196.18
254.82
328.95
385.02
496.63
556.07
515.91
Tangible Book Value per Share
1,519
1,519
1,519
1,519
1,519
1,519
1,500
1,445
1,409
1,462
1,495
1,510
1,512
1,488
1,488
1,481
1,487
Basic Weighted Avg Shares
316,009
328,214
386,686
402,294
467,359
489,506
525,026
514,164
587,775
599,481
628,897
613,842
703,303
820,209
921,863
1,036,171
477,989
Sales/Revenue/Turnover
20.03
19.08
16.3
13.23
13.97
13.78
15.56
17.07
18.47
17.79
17.59
16.03
16.49
14.31
15.2
15.22
15.4
Operating Margin (%)
19,909
20,392
28,835
32,553
39,881
40,692
44,674
34,471
42,035
44,035
52,358
53,932
58,882
70,238
76,745
85,449
39,957
Depreciation Expense
40,721
32,338
24,167
47,014
34,096
38,470
50,676
55,003
91,295
79,470
85,211
77,268
88,813
89,325
106,374
116,978
56,282
Net Income, GAAP
35.64
37.15
51.21
9.98
35.5
39.93
34.18
26.69
14.47
22.8
20.13
20.46
22.43
23.09
24.47
24.32
24.35
Effective Tax Rate (%)
12.89
9.85
6.25
11.69
7.3
7.86
9.65
10.7
15.53
13.26
13.55
12.59
12.63
10.89
11.54
11.29
11.77
Profit Margin (%)
130,700
157,664
98,870
171,111
150,049
282,511
205,911
80,797
232,029
255,810
248,762
312,600
380,992
393,395
342,964
482,531
448,155
Working Capital
463
636
130,999
159,151
117,068
219,652
159,343
210,335
288,776
225,135
195,870
218,497
224,875
220,714
74,978
159,838
159,804
LT Debt
317,139
335,456
352,537
437,909
496,245
573,523
511,544
491,522
550,435
698,112
754,882
856,662
1,012,313
1,111,063
1,327,090
1,368,535
1,313,508
Total Equity
12.32
11.35
6.85
8.14
6.49
5.42
6.9
8.14
10.65
8.97
9.08
7.3
7.55
6.89
7.17
7.57
3.67
Return on Invested Capital (%)
11.27
8.51
5.66
9.69
6.83
6.97
8.27
8.47
10.11
8.98
9.43
7.67
8.34
8.19
9.15
9.92
4.7
Return on Capital (%)
12.04
8.77
7.19
15.17
9.99
10.44
12.62
11.32
15.47
12.11
11.92
9.92
10.45
9.93
11.16
11.42
5.66
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
156,870
- -
15,000
LT Borrowings
74,978
- -
159,804
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,485
- -
1,484
Market Capitalization
4,182,654
3,922,196
4,230,701

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
722,116
- -
679,198
Cash, Cash Equivalents & STI
231,041
- -
195,263
Accounts Receivable, Net
178,710
- -
164,624
Inventories
286,599
- -
286,051
Total Current Liabilities
379,152
- -
231,043
Payables & Accruals
- -
- -
- -
ST Debt
156,870
- -
15,000
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.62%
12.79%
3.12%
Free Cash Flow
24.16%
38.96%
90.12%
Net Income, GAAP
13.58%
7.05%
9.97%
Sales/Revenue/Turnover
8%
10.72%
12.4%
Total Cash Common Dividend
12.63%
11.8%
11.28%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
215,252
228,621
239,077
238,912
921,863
2025
- -
- -
- -
- -
1,036,171
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15.14
18.49
20.03
- -
71.5
2025
- -
- -
- -
- -
79.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10.36
0.14
10.98
- -
21.52
2025
- -
- -
- -
- -
24.06
2026
- -
- -
- -
- -
- -
Similar Companies
Avantor, Inc. (AVTR)
Baxter International Inc. (BAX.SW)
QuidelOrtho Corporation (QDEL)
Tofflon Science and Technology Group Co., Ltd. (300171.SZ)
AptarGroup, Inc. (ATR)
Straumann Holding AG (SAUHF)
Business
Terumo Corporation is a Japanese multinational company specializing in medical devices and healthcare products. Its core products and services include the manufacture and sale of cardiovascular systems; blood management systems such as blood transfusion and blood collection devices; vascular intervention devices; infusion systems including infusion pumps and disposables; general hospital supplies; and diagnostic systems. Terumo operates globally, serving hospitals, clinics, and healthcare providers primarily across Asia, Europe, and the Americas. The company was founded in 1921 and is headquartered in Tokyo, Japan. In recent years, Terumo Corporation has focused on strategic expansion and innovation within the medical technology sector. Notably, the company has introduced new product lines in vascular intervention and infusion therapy, enhancing its position in minimally invasive therapies and critical care. Terumo has also engaged in strategic acquisitions and partnerships aimed at broadening its product portfolio and geographic reach, including innovative collaborations to advance technological capabilities in patient monitoring and medical device integration. These moves underscore Terumo’s commitment to advancing healthcare through sustained product development and strategic growth initiatives within the last one to two years. Terumo operates primarily in the healthcare industry sector, targeting hospitals, healthcare systems, and medical professionals worldwide. Its business segments include cardiovascular systems, blood management systems, and general hospital supplies, providing a comprehensive suite of medical products and services designed to improve patient outcomes. The company maintains a strong presence in key global markets, including Japan, the United States, Europe, and emerging markets in Asia, supported by a network of manufacturing facilities and subsidiaries. Overall, Terumo Corporation delivers specialized medical devices and healthcare solutions, with a continued focus on innovation, market expansion, and strategic alliances to maintain its leadership in the global healthcare market. The company’s long history since 1921 and its Tokyo headquarters reflect its established position as a trusted global medical technology provider.